Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
0.7016
+0.0028 (0.40%)
Jun 20, 2025, 4:00 PM - Market closed
Ironwood Pharmaceuticals Stock Forecast
IRWD's stock price has decreased by -87.69% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts that cover Ironwood Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $4.94, which forecasts a 604.1% increase in the stock price over the next year. The lowest target is $0.7 and the highest is $14.
Price Target: $4.94 (+604.1%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 15, 2025.
Analyst Ratings
The average analyst rating for Ironwood Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $7 → $1 | Buy → Hold | Downgrades | $7 → $1 | +42.53% | Apr 15, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $8 → $0.7 | Strong Buy → Hold | Downgrades | $8 → $0.7 | -0.23% | Apr 15, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $3 → $1 | Hold | Maintains | $3 → $1 | +42.53% | Apr 14, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $23 → $14 | Buy | Maintains | $23 → $14 | +1,895.44% | Jan 30, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $10 → $8 | Strong Buy | Maintains | $10 → $8 | +1,040.25% | Jan 22, 2025 |
Financial Forecast
Revenue This Year
276.01M
from 351.41M
Decreased by -21.46%
Revenue Next Year
262.50M
from 276.01M
Decreased by -4.89%
EPS This Year
0.19
from 0.01
Increased by 3,311.68%
EPS Next Year
0.12
from 0.19
Decreased by -37.84%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 288.2M | 299.6M | 189.0M | ||
| Avg | 276.0M | 262.5M | 183.6M | ||
| Low | 258.8M | 220.2M | 176.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -18.0% | 8.5% | -28.0% | ||
| Avg | -21.5% | -4.9% | -30.1% | ||
| Low | -26.3% | -20.2% | -32.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.22 | 0.24 | -0.11 | ||
| Avg | 0.19 | 0.12 | -0.10 | ||
| Low | 0.16 | - | -0.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3,886.6% | 28.0% | - | ||
| Avg | 3,311.7% | -37.8% | - | ||
| Low | 2,734.9% | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.